Connect with us

Business

Q BioMed Inc (OTCMKTS:QBIO) Reports Settlement Of Convertible Debt

Published

on

Q BioMed Inc (OTCMKTS:QBIO) reported that all loans and convertible notes have been settled, including the convertible notes worth $4 million that had been issued following a Securities Purchase Deal dated November 29, 2016.

The firm completed its FY2017 with no outstanding convertible debt or loan. Denis Corin, the CEO of Q BioMed, expressed that they are extremely delighted to end the fiscal year 2017 with a robust balance sheet and with a remarkable financial and capital structure from which to persist to build their business. More information pertaining to the closure of these debts can be seen in Form 8-K submitted with the U.S. SEC.

The details

In unrelated news, Q BioMed reported that Dr. Helen Tager-Flusberg will be a member of its advisory committee formed for QBM-001. The drug is being evaluated for pediatric developmental nonverbal ailments in kids within the autism spectrum ailments. Dr. Tager-Flusberg has offered the protocol for achieving the primary endpoint of the intended study for QBM-001.

Denis Corin, the CEO of Q BioMed, expressed that they are delighted to have Dr. Tager-Flusberg join their advisory committee for QBM-001. She is a leader in her field, focused on autism spectrum ailment to design language and speech assessment initiatives to capture their progress. Dr. Tager-Flusberg has committed much of her career to advancing substantial approaches to evaluate expressive language development in children and toddlers with autism spectrum and developmental delay disorders.

Her newest approach is named ELSA-T, which uses validated constituents for language development, together with more flexibility with the practice to better adapt to the requirements of a clinical study and to the needs of patients and caregivers. Dr. Tager-Flusberg expressed that communication matters for everyone, and for her it is all the more motivating to be able to assist advance language assessment tools, like ELSA-T, to assess language and speech development for toddlers struggling with pediatric developmental delay and autism spectrum ailment.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of MMJReporter.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure

BRANDS

DETAILS

SCORE

PRODUCT SITES

  • Certified Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49

9.8

30% OFF Today! “30 0FF”

  • All Natural
  • Made In U.S.A
  • Lab Tested
  • Price From $69

9.7

  • All Natural
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99

9.6

  • All Natural
  • Made In U.S.A
  • Oral Mist
  • Price From $39

9.5

BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49
SCORE

9.8

PRODUCT SITE
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Lab Tested
  • Price From $69
SCORE

9.7

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99
SCORE

9.6

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Oral Mist
  • Price From $39
SCORE

9.5

PRODUCT SITE VIEW PRODUCTS
Advertisement

Symbol        Alert        High        Gain

 

  VBIO          $0.67       $4.10      500%

  IMLFF        $0.11       $0.57      400%

  CMXC        $0.25       $0.45      80%

  REPCF       $0.54       $0.79      48%

 

Get Your Latest Winner Delivered to Your Inbox!

FREE

For The Next 48 Hours

Advertisement
Advertisement
Advertisement
Advertisement
Advertisement